Keyphrases
2-dose
12%
Adult Patients
12%
Anti-CD19
100%
Anti-CD19 chimeric Antigen Receptor T Cells
12%
Anti-tumor Response
12%
Axicabtagene Ciloleucel
25%
Blood Count
12%
Bone Marrow Aplasia
100%
CD19
25%
Center Experience
100%
Chimeric Antigen Receptor T Cells (CAR-T)
100%
Chimeric Antigen Receptor T-cell Therapy
12%
Commercially Available
12%
Complete Resolution
12%
Cytopenia
62%
Diffuse Large B-cell Lymphoma (DLBCL)
12%
Eltrombopag
25%
Hematopoietic Recovery
12%
Hemoglobin
12%
Independency
12%
Initial Dose
12%
Maximum Tolerated Dose
12%
Median Time
25%
Neutrophils
12%
No Toxicity
12%
Optimal Treatment
12%
Platelets
37%
Prolonged Cytopenia
12%
Romiplostim
12%
Severe Neutropenia
12%
Subcutaneous Injection
12%
Thrombopoietin Receptor Agonists (TPO-RAs)
100%
Tisagenlecleucel
25%
TPO Receptor Agonists
100%
Transfusion
12%
Transfusion Requirements
12%
Unmet Needs
12%
Pharmacology, Toxicology and Pharmaceutical Science
Axicabtagene Ciloleucel
22%
Bone Marrow Aplasia
100%
Chimeric Antigen Receptor
100%
Cytopenia
66%
Diffuse Large B Cell Lymphoma
11%
Eltrombopag
22%
Neoplasm
11%
Neutropenia
11%
Receptor Agonist
100%
Romiplostim
11%
Subcutaneous Injection
11%
Thrombopoietin Receptor
100%